Outlook Wealth Advisors LLC Makes New $263,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Outlook Wealth Advisors LLC purchased a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 629 shares of the pharmaceutical company’s stock, valued at approximately $263,000.

A number of other hedge funds have also modified their holdings of VRTX. OFI Invest Asset Management acquired a new position in Vertex Pharmaceuticals in the 3rd quarter worth approximately $25,000. University of Texas Texas AM Investment Managment Co. purchased a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at $25,000. Arlington Trust Co LLC increased its stake in shares of Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 33 shares during the period. Annapolis Financial Services LLC purchased a new position in shares of Vertex Pharmaceuticals during the first quarter worth $27,000. Finally, ICA Group Wealth Management LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter valued at $28,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Stuart A. Arbuckle sold 4,295 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the sale, the chief operating officer now directly owns 75,718 shares in the company, valued at $31,819,732.32. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, COO Stuart A. Arbuckle sold 4,295 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the transaction, the chief operating officer now directly owns 75,718 shares in the company, valued at $31,819,732.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now owns 55,804 shares in the company, valued at approximately $23,755,762.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,381 shares of company stock valued at $5,203,249. 0.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

VRTX has been the topic of several analyst reports. Guggenheim increased their price target on Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Sanford C. Bernstein cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, February 2nd. JPMorgan Chase & Co. upped their price objective on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Canaccord Genuity Group cut shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and raised their price objective for the stock from $332.00 to $379.00 in a research note on Wednesday, January 24th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $500.00 target price on shares of Vertex Pharmaceuticals in a research note on Monday, April 15th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $429.45.

Vertex Pharmaceuticals Price Performance

VRTX traded down $0.22 during trading on Friday, reaching $397.48. The company’s stock had a trading volume of 682,467 shares, compared to its average volume of 909,553. The company has a market cap of $102.73 billion, a price-to-earnings ratio of 28.62, a PEG ratio of 1.87 and a beta of 0.35. The firm has a fifty day simple moving average of $411.60 and a two-hundred day simple moving average of $398.67. Vertex Pharmaceuticals Incorporated has a 1 year low of $320.01 and a 1 year high of $448.40. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating the consensus estimate of $3.85 by $0.35. The firm had revenue of $2.52 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same quarter last year, the firm earned $3.33 earnings per share. As a group, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.